Bayer: Peptide deal with Gubra

The partnership utilises Gubra’s machine learning-based peptide drug discovery platform for fast screening and identification of potent therapeutic peptide candidates. In return, the Danish company will receive an undisclosed upfront payment, as well as potential future development and commercialisation milestones of up to €216m.

“We are very pleased to enter this research collaboration and license agreement with Bayer,” said Henrik Blou, CEO of Gubra, which was founded in 2008. “We have used streaMLine, our proprietary machine learning-based target and peptide drug discovery platform, to conceive this promising programme currently undergoing preclinical maturation. We are pleased that the potential of our technology is being recognised by such a qualified partner capable of advancing innovative medicines into the clinic.”

Cardiorenal disease encompasses a range of acute and chronic disorders that involve both the heart and the kidney. Treatment is often challenging as many heart medications may worsen kidney function, and vice versa.  “These disorders are associated with a high morbidity and mortality globally and currently available treatments are not optimal for all patients. Consequently, cardiorenal diseases cause a significant burden on health care systems around the world,” the companies state.